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Abstract
Background: Flat adenomas are a subgroup of colorectal adenomas that have been associated with a distinct biology and
a more aggressive clinical behavior compared to their polypoid counterparts. In the present study, we aimed to compare
the mutation spectrum of 14 cancer genes, between these two phenotypes.
Methods: A consecutive series of 106 flat and 93 polypoid adenomas was analyzed retrospectively for frequently occurring
mutations in ‘‘hot spot’’ regions of KRAS, BRAF, PIK3CA and NRAS, as well as selected mutations in CTNNB1 (b-catenin), EGFR,
FBXW7 (CDC4), PTEN, STK11, MAP2K4, SMAD4, PIK3R1 and PDGFRA using a high-throughput genotyping technique.
Additionally, APC was analyzed using direct sequencing.
Results: APC mutations were more frequent in polypoid adenomas compared to flat adenomas (48.5% versus 30.3%,
respectively, p = 0.02). Mutations in KRAS, BRAF, NRAS, FBXW7 and CTNNB1 showed similar frequencies in both phenotypes.
Between the different subtypes of flat adenomas (0-IIa, LST-F and LST-G) no differences were observed for any of the
investigated genes.
Conclusion: The lower APCmutation rate in flat adenomas compared to polypoid adenomas suggests that disruption of the
Wnt-pathway may occur via different mechanisms in these two phenotypes. Furthermore, in contrast to previous
observations our results in this large well-defined sample set indicate that there is no significant association between the
different morphological phenotypes and mutations in key genes of the RAS-RAF-MAPK pathway.
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Introduction
It is now widely accepted that phenotypically different types of
colorectal adenomas exist. Whereas the terms polyps and
adenomas have long been used as synonyms, in 1985 Muto et al
were the first to describe ‘small flat adenoma’ in the colorectum
[1]. These flat adenomas have, until quite recently, been
considered rare in Western countries, in contrast to Japan where
they have been reported to represent 12–40% of colorectal
adenomas or early carcinomas [2,3]. However, due to advanced
endoscopic imaging techniques and increasing awareness, similar
incidence of flat adenomas are now reported in the West [4–6].
Flat lesions have been associated with a more aggressive behavior
and are more likely to contain advanced histology [6,7]. Flat
adenomas therefore represent an important piece of the puzzle of
colorectal cancer (CRC) pathogenesis.
CRC results from the accumulation of multiple genetic and
epigenetic alterations in the epithelial cells that line the large
intestine. These events first give rise to an adenoma that, in
a minority of cases progresses into an invasive, metastasizing
adenocarcinoma [8]. These genetic and epigenetic alterations
affect different pathways that regulate multiple biological processes
critical to cancer development [9].
One of these is the Wnt-signaling pathway, and somatic
mutations in the tumor suppressor gene, APC, a key-player in
the Wnt-pathway, are common in CRC [10]. Wild type APC
forms a complex with other proteins to coordinate b-catenin
degradation. When APC is mutated, degradation of b-catenin fails,
resulting in translocation of b-catenin to the nucleus where it
initiates transcription of key proliferation genes. We previously
found significantly more chromosome 5q loss (APC locus) in flat
adenomas compared to polypoid adenomas [11]. Next to
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disruption of APC, mutations in CTNNB1 (b-catenin) are a (less
common) way to constitutively activate the Wnt-signaling pathway
[12].
Another key pathway in CRC tumorigenesis is the RAS-RAF-
MAPK pathway, which is known to be one of the major pathways
in the pathogenesis of CRC. Disruption of this pathway at multiple
levels occurs in many cancer types. Interestingly, initial molecular
studies indicated a lower incidence of KRAS mutations in flat
lesions compared to polypoid lesions [13,14], while more recent
studies contradict these findings [15,16]. Similar contradicting
results have been described for other mutated genes, including
BRAF [16,17].
Most studies investigating flat adenomas, however, have been
performed in relatively small and selected sample series, which
may cause these conflicting findings. To further elucidate the role
of the RAS-RAF-MAPK pathway in colorectal adenomas it is
necessary to determine mutation frequencies of RAS-RAF-MAPK
pathway genes, including upstream regulators and downstream
effectors. For many other important cancer related genes, even less
data on mutation status in flat adenomas exist, and consequently,
much of the genomics of flat colorectal adenomas remains to be
elucidated.
The aim of the present study was to address this issue in a more
systematic fashion, by analyzing the mutation spectrum of 14 well-
known cancer genes (i.e. BRAF, NRAS, KRAS, PIK3CA, PIK3R1,
EGFR, PTEN, MAP2K4, SMAD4, FBXW7 (CDC4), CTNNB1 (b-
catenin), STK11, PDGFRA and APC) [18] in a large well-defined
series of flat and polypoid adenomas using a high-throughput
genotyping technique.
Methods
Ethical Statement
Collection, storage and use of archival tissue and patient data
were performed in compliance with the ‘‘Code for Proper
Secondary Use of Human Tissue in the Netherlands’’ (http://
www.fmwv.nl and www.federa.org). This study was approved by
the VU University medical center (2011–03), the Leeds University
(CA02/014 Leeds (West)) and the Hospital Vitkovice (EK/140/
10).
This study followed the ethical guidelines of the Institutional
Review Board (IRB). The IRB waived the need for consent for use
of the archive samples, and the samples were analyzed anony-
mously.
Patient and Sample Selection
Formaldehyde-fixed, paraffin-embedded (FFPE) tissue samples
from both a consecutive series of polypoid adenomas and
a consecutive series of flat colorectal adenomas were collected at
three different institutes. Excluding criteria were hereditary CRC,
inflammatory bowel disease (IBD), all hyperplastic polyps as well
as all adenomas smaller than 5 mm (except for two depressed
adenomas, subtype IIc, since these were of clinical interest and
unequivocally non-polypoid), resulting in a series of 106 flat
adenomas and 93 polypoid adenomas. Selective chromo-endos-
copy (dye-spraying), which has been suggested to enhance the
detection rate of flat lesions [19] was used when applicable. Of
these 199 samples, 55 adenomas originated from 53 patients from
the Leeds General Infirmary, Leeds, UK, collected between 1995–
2007 [5], 51 adenomas originated from 47 patients from the
Hospital Vitkovice, Ostrava, Czech Republic, collected between
2006–2008 [20] and 93 adenomas originated from 76 patients
from the VU University medical center, Amsterdam, The
Netherlands, collected between 1990–2008. Endoscopically, flat
adenomas were defined as height ,2–3 mm. Classification of the
adenomas was performed according to the Paris classification [21].
Five categories of adenomas were distinguished; polypoid/
pedunculated type, 0-Ip (n = 93), slightly elevated type, 0-IIa
(n = 40), slightly depressed type, 0-IIc (n = 4), lateral spreading type
flat, LST-F (n= 41) and lateral spreading type granular, LST-G
(n= 21), with LST being defined as a subclass of type 0-IIa
measuring more than 10 mm in maximum diameter [22]. A
summary of all clinical characteristics is listed in Table 1.
DNA Isolation
DNA from FFPE material was isolated following macro-
dissection (.70% dysplastic cells) as described before [23] with
a few modifications. In stead of one day, a five day incubation
period with lysis buffer (ATL buffer, QIAmp, DNA micro-kit,
Qiagen, Venlo, The Netherlands) and freshly added (once every
day) proteinase K (10 ml of 20 ng/ml) was performed. DNA was
isolated using a column based method (QIAmp, DNA micro-kit,
Qiagen, Venlo, The Netherlands). DNA concentrations and
purities were measured on a Nanodrop ND-1000 spectrophotom-
eter (Isogen, IJsselstein, The Netherlands).
Table 1. Clinical characteristics of the 199 investigated
adenomas.
Polypoid Adenomas Flat Adenomas
Total n =93 (%) n =106 (%)
Histology
Tubular 46 (49) 73 (69)
Tubulovillous 36 (40) 27 (25)
Villous 10 (11) 2 (2)
Serrated (SSL) 0 (0) 3 (3)
Serrated (TSA) 0 (0) 1 (1)
Dysplasia
LGD (mild) 11 (12) 10 (9)
LGD (moderate) 69 (74) 86 (81)
HGD (severe) 13 (14) 10 (9)
Size (mm) 17.0 [5–64] 16.2 [3–100]
Male/Female 41/52 66/40
Location
Proximal 22 (24) 69 (65)
Distal 34 (37) 19 (18)
Rectum 33 (35) 16 (15)
Unknown 4 (4) 2 (2)
Age (years) 68.9 [40–90] 68.0 [45–87]
Paris classification
0-Ip 93 (100)
0-IIa 40 (38)
0-IIc 4 (4)
LST-G 21 (15)
LST-F 41 (39)
All adenomas were classified endoscopically using the Paris classification; SSL;
sessile serrated lesion, TSA; traditional serrated adenoma, LGD, low grade
dysplasia; HGD, high grade dysplasia; proximal colon includes caecum,
ascending and transverse colon; distal colon includes sigmoid, descending and
splenic flexure.
doi:10.1371/journal.pone.0041963.t001
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Mutation Analysis
The Catalogue of Somatic Mutations in Cancer (COSMIC)
database [24] was queried for mutations as described before [25].
Briefly, the most frequent mutations occurring in large intestinal
cancer for KRAS, BRAF, NRAS and PIK3CA were selected. This
resulted in a coverage of 97.9%, 97.3%, 81.4% and 68.8% for
respectively BRAF, KRAS, PIK3CA and NRAS mutations (Figure 1,
Table S1). For other genes of interest, no large series of CRC had
been profiled or no specific mutation hot-spot could be identified.
Therefore, for these genes, i.e. CTNNB1, EGFR, FBXW7, PTEN,
STK11, MAP2K4, NRAS, SMAD4, PIK3R1, and PDGFRA, the
COSMIC database was queried for the nucleotides most
frequently mutated in all cancer types present in the database
(Figure 1, Table S1).
Samples were genotyped for the respective nucleotide positions
using a high-throughput matrix-assisted laser desorption/ioniza-
tion–time of flight (MALDI-TOF) mass spectrometer (Spectro-
READER, Sequenom, San Diego, CA, USA), at the Vesalius
Research Center (Leuven, Belgium) as described previously
[25,26]. The sensitivity and accuracy of this technique have been
documented before [25,26]. Samples were considered of sufficient
quality when more than 75% of the investigated nucleotide
positions were reliably genotyped.
APC Mutation Analysis
Mutations in the mutation cluster region (MCR1286-1513) of
APC were analyzed by sequencing between codons 1260 and 1530
by four flanking PCRs followed by two semi-nested PCRs as
described previously [27], using a 3500 Genetic Analyzer (Applied
Biosystems Foster city, CA, USA). VectorNTI (Invitrogen) and
Mutation Surveyor (SoftGenetics) were used for data analysis.
Mutations were confirmed by independent PCR reactions and
sequencing.
For 39 adenomas APC mutation status was determined and
published previously [28]. Briefly, APC was analyzed using four
flanking PCRs for the region 1291–1541 and sequenced on an
ALFExpress (Amersham Biosciences Europe GmbH, Roosendaal,
The Netherlands) DNA sequencer. Data was analyzed using the
ALFwin sequence analyzer 2.10 program (Amersham Biosciences
Europe GmbH).
Microsatellite Instability (MSI) Status
MSI analysis was performed using the MSI Analysis System
(MSI Multiplex System Version 1.2, Promega, Madison, WI,
USA) consisting of five quasi-monomorphic mononucleotide
markers (BAT-25, BAT-26, NR-21, NR-24, MONO-27) accord-
ing to the manufacturer’s instructions. PCR products were
separated using a 3130 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA), and analyzed using GeneScan3100
(Applied Biosystems). An internal lane size standard was added
to the PCR samples for accurate sizing of alleles and to adjust for
run-to-run variations. When two or more markers were instable,
the sample was interpreted as microsatellite instable (MSI), all
other samples were classified as microsatellite stable (MSS).
Data Analyses
To deal with partly missing data for samples with one or more
unsuccessful assays, random imputation was used. This avoids
underestimation (respectively overestimation) of the mutation
frequency for one single gene that would be caused by discarding
samples that had one or more unsuccessful assays, but showed
evidence (respectively no evidence) of mutations for the successful
assays. More specifically, each missing value was imputed to be
a mutation with probability equal to the proportion of mutations
at that specific nucleotide position, as computed from the non-
missing data. Multiple random imputations were applied to obtain
a more precise estimate of mutation percentage. Finally, odds
ratios and differences thereof were estimated in order to compare
the two groups. Using the imputed data, differences in frequencies
of mutations between the different lesion types were evaluated by
chi-square or Fisher’s exact test where appropriate. The results
were pooled over the multiple random imputations, thereby
accounting for the additional noise introduced by the imputation
process.
Statistical language R, version 2.9.0 was used for the imputation
and SPSS version 15.0 was used to perform the chi-square or
Fisher’s exact test. All reported p-values are two-sided, and a p-
value ,0.05 was considered statistically significant.
Results
In total 93 polypoid adenomas and 106 flat adenomas were
analyzed for 13 genes (BRAF, NRAS, KRAS, PIK3CA, PIK3R1,
Figure 1. Total coverage of the 14 genes investigated, based on the COSMIC database. On the x-axis the analyzed gene. On the y-axis the
mutation percentage is shown, based on large intestine carcinomas in the COSMIC database. In grey, the mutation percentages according to the
COSMIC database, in black the mutation percentage covered by this study, on top of the bars the total number of analyzed samples found in the
COSMIC database.
doi:10.1371/journal.pone.0041963.g001
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EGFR, PTEN, MAP2K4, SMAD4, FBXW7, CTNNB1, STK11 and
PDGFRA) at 82 nucleotide positions. After excluding unreliable
nucleotide positions (genotyped in less then 75% of all samples), 75
positions were left to be investigated. No mutations were found for
eight genes, i.e. PIK3CA, PIK3R1, EGFR, PTEN, MAP2K4,
SMAD4, STK11 and PDGFRA (Table S2) leaving five genes,
analyzed at 23 nucleotide positions, that contained mutations
(BRAF, NRAS, KRAS, FBXW7, CTNNB1). For APC, the MCR was
successfully sequenced and analyzed for 155 adenomas, i.e. 81
polypoid adenomas and 74 flat adenomas. (Figure 1, Table S1 and
S2).
KRAS
For KRAS, eight out of the nine nucleotide positions tested
showed sufficient results (codon 12: c.34G.CAT, c.35G.ATC,
codon 13: c.38G.ACT, c.39C.AGT, codon 59: c.175G.A,
codon 61: c.181C.AG, c.182A.TGC, c.183A.CT) covering
98.85% of the mutations described in colorectal adenomas
(Figure 1, Table S1C). Both flat and polypoid adenomas were
most frequently mutated at codon 12, position 35 (60% (17/28)
and 59% (20/33) for flat and polypoid adenomas, respectively) and
transition from G.A was the most common nucleotide shift for
both phenotypes (53% for flat adenomas and 50% for polypoid
adenomas) (Table S2C and S3). The mutation at position
c.182A.T (p.Q61L), was found in only one flat adenoma and
has not been described before in colorectal adenomas. The
nucleotide positions 39, 175, 181 and 183 showed no mutations
(Table S2C). A significant difference between flat adenomas and
polypoid adenomas was found at codon 12, position 34 (10.7% in
polypoid adenomas versus 2.9% in flat adenomas, p = 0.05) and
for codon 12, position 34 and 35 together (32.6% versus 20.0%,
respectively, p = 0.05).
Overall, KRAS mutations were observed in 36.30% (95%
confidence interval (CI) 26.57%-46.92%) of polypoid adenomas
and 27.85% (95% CI 19.58%-37.39%) of flat adenomas (Figure 2,
Table S2C), resulting in no statistically significant difference
(p = 0.2, odds ratio 0.67 (95% CI 0.37%-1.24%)).
Relationship between KRAS Mutation and Adenoma
Location
In the present series, flat adenomas were more commonly
located proximal than polypoid adenomas (65% versus 24%,
respectively, p= 7.7*1029). No significant difference in overall
KRAS mutation frequency was found after stratifying the
adenomas by location (data not shown).
Relationship between KRAS Mutation and Subtypes of
Flat Adenomas
By analyzing the different subtypes of flat adenomas separately,
no relationship was found between KRAS mutation and any of the
subtypes. None of the four type IIc lesions, showed a KRAS
mutation. The other three flat adenoma subtypes showed overall
KRAS mutation rates of 26.8% (95% CI 14.22 to 42.94%), 26.73%
(95% CI 14.16%-42.82%) and 34.67% (95% CI 15.58%-58.26%)
for IIa, LST-F and LST-G, respectively. These KRAS mutation
frequencies were not significantly different compared to KRAS
mutation frequencies of polypoid adenomas (data not shown).
BRAF
Two of the four nucleotide positions known to carry BRAF
mutations in CRC were successfully analyzed, including
c.1799T.A (p.V600E), (with 88.64% the most frequently mutated
BRAF position in adenomas, Figure 1, Table S1A). In the present
study, the BRAF mutation frequency was 2.83% (95% CI 0.59%-
8.05%) in flat adenomas and 2.15% (95% CI 0.26%-7.55%) in
polypoid adenomas (p= 1, Figure 2, Table S2A and S3). These
percentages are similar to the percentages found in the COSMIC
database for these nucleotide positions (Table S1A and S2A). Of
the five adenomas with a BRAF mutation, three were detected in
a serrated phenotype (histologically, one was a traditional serrated
adenoma (TSA) and two were sessile serrated lesion (SSL), all three
were classified as a LST-F subtype). Four were found in adenomas
proximally located, which included these three serrated flat
adenomas (Table S3).
NRAS, FBXW7 and CTNNB1
Two NRAS mutations were found, all in the distal colon,
c.37G.C (p.G13R) in polypoid adenomas 1.08% (95% CI
0.03%-5.85%) and c.182A.G (p.Q61R) in flat adenomas 0.94%
(95% CI 0.02%-5.14%). Both have not been described in
adenomas before (Figure 2, Table S2B and S3). In the COSMIC
database 2.8% NRAS mutations have been reported in adenomas
(based on 142 samples, Figure 1, Table S1B).
Four FBXW7 mutations were discovered, one in a flat adenoma
(c.1394G.A (p.R465H)) and three in polypoid adenomas, namely
c.832C.T (p.R278*), and two times c.1513C.T (p.R505C). This
last mutation has not been described before in adenomas. One of
the polypoid adenomas with a c.1513C.T (p.R505C) FBXW7
mutation also harbors a KRAS mutation, (c.35G.A) (Table S2J
and S3). The FBXW7 mutation frequency was 3.23% (95% CI
0.67%-9.14%) for polypoid adenomas and 1.13% (95% CI 0.07%-
5.44%) for flat adenomas (Figure 2, Table S2J) which was similar
to reported frequencies in the COSMIC database (4.14% based
on 145 samples, Figure 1, Table S1J and S2J ). One polypoid and
one flat adenoma harbored a CTNNB1 mutation, both at the same
nucleotide position c.134C.T (p.S45F) and both adenomas
contained no APC truncating mutation. One of the CTNNB1
mutations was found in a sample that also showed a KRAS
(c.35G.A) mutation (Table S3). The CTNNB1 mutation frequen-
cy was 1.08% (95% CI 0.03%-5.85%) for polypoid adenomas and
0.94% (95% CI 0.02%-5.14%) for flat adenomas (Figure 2, Table
Figure 2. The mutation percentage for the flat and polypoid
adenomas. Only genes that show a mutation in one of the adenoma
types are included. White bars represent flat adenomas and grey bars
polypoid adenomas. Percentages are calculated using random impu-
tation, horizontal bars represent the 95% confidence interval.
doi:10.1371/journal.pone.0041963.g002
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S2K), giving no significant differences between the two pheno-
types. The percentages found were in the same range as for the
colorectal adenomas described in the COSMIC database (based
on 964 samples, Figure 1, Table S1K and S2K).
APC
According to the COSMIC database, the MCR harbors
76.37% of all the mutations described in the APC gene for
adenomas (Figure 1, Table S1N). In the current study the position
c.4348C.T (p.R1450*) was the most frequently mutated site. The
vast majority of mutations found in this study are predicted to
result in a premature stop codon (truncating mutation), except for
four silent mutations and four missense mutations (Table S2N and
S3). Two of these mutations were found in polypoid adenomas and
six in flat adenomas. The truncating mutations involved 15
nucleotide substitutions, 5 nucleotide(s) insertions and 25 nucleo-
tide(s) deletions for polypoid adenomas and 13 nucleotide
substitutions, 3 nucleotide(s) insertions and 8 nucleotide(s) dele-
tions for flat adenomas. Four samples contained a double mutation
in APC, i.e. three flat adenomas and one polypoid adenoma. Three
of these samples harbored a missense mutation (c.4326T.A
(p.P1442P)) next to a truncating mutation and one flat adenoma
contained two truncating mutations (c.4259_4272del14
(p.P1420fs*2) and c.4348C.T (p.R1450*) (Table S2N and S3)).
Overall, the mutation rate for truncating mutations in APC was
significantly higher in polypoid adenomas compared to flat
adenomas (48.49% (95% CI 37.23%-59.87%) versus 30.27%
(95% CI 20.13%-42.05%), respectively, p = 0.02, odds ratio 0.46,
95% CI 0.25%-0.90%, Figure 2, Table S2N).
Relationship between APC Mutation and Adenoma
Location
After stratification for anatomical location the difference in APC
mutation frequency between flat adenomas and polypoid adeno-
mas persisted for the distal colon with 61.7% (37/60) of polypoid
adenomas showing APC mutations compared to 31.0% (9/29) of
flat adenomas. In the proximal colon, however, this difference
could not be detected (33.3% (6/18) in polypoid adenomas versus
31.1% (14/45) in flat adenomas).
The exact mutation positions in the APC gene, result into
different numbers of b-catenin down-regulating motifs (20 amino
acid repeats) in the truncated protein. Mutations found in the
proximal colon lead to APC proteins that in 15% (3/20) harbor
one repeat and in 85% (17/20) two repeats whereas in the distal
colon these figures were exactly fifty/fifty (23/46, harbored one
repeat, and 23/46 harbored two repeats, proximal versus distal,
p = 0.007). However, the number of repeats did not differ between
flat and polypoid adenomas, also not after stratification for
location.
Relationship of APC Mutation and Subtypes of Flat
Adenomas
Types IIa, LST-G and LST-F flat adenomas all contained
significantly fewer APC mutations compared to polypoid adeno-
mas (IIa: 29.6% (8/27), LST-G: 25% (3/12), LST-F: 34.4% (11/
32) vs polypoid 55.6% (45/81) p = 0.02, 0.05 and 0.04, re-
spectively). Of the three successfully annotated IIc type flat
adenomas, one showed a mutation (c.4285C.T (p.Q1429*))
(Table S3).
Between the different subtypes, there was no difference in APC
mutation frequency, although mutations in subtype IIa did not
include deletions and mutations in both LST types did not include
insertions (IIa contained 6 substitutions and 3 insertions, LST
contained 12 substitutions and 8 deletions, p = 0.006). There was
no difference found between the amount of b-catenin down-
regulating repeats left in the truncated APC protein between the
different subtypes.
MSI
In 153 out of 199 adenomas (80 polypoid and 73 flat adenomas)
MSI status could be successfully determined. Of these, only one
flat adenoma (type IIa) showed MSI, no mutations or a specific
phenotype were associated with this adenoma (Table S3).
Discussion
Awareness of the clinical relevance of flat colorectal adenomas
has grown over the last two decades [6]. As a consequence
multiple studies have explored their pathogenesis. Some of these
studies have suggested a different biology for flat adenomas, which
was contradicted by other studies. Often, these claims were based
on a limited sample size and many studies used suboptimal
classification [29,30]. Moreover, many studies had limited sample
size, which hampers generalization of the findings [30,31]. The
aim of the present study was to investigate in parallel, in a large
multi-centre well-defined series of flat and polypoid adenomas, the
mutation status of 14 genes known to be involved in CRC. The
genes studied are involved in a number of different signal
transduction pathways.
RAS-RAF-MAPK Pathway
The RAS-RAF-MAPK pathway is a key signal transduction
pathway in many cancers including CRC and was investigated in
the current study by examining the mutations status of KRAS,
NRAS, BRAF and MAP2K4. In the context of flat colorectal lesions
this pathway is still controversial, since it has been reported that
KRAS mutations would be uncommon in flat adenomas [13,14],
while later studies claimed the opposite [16] or did not detect
a difference with polypoid lesions [15,32]. The present study
involving a large well-defined sample series, supports these latter
studies which do not detect a significant difference between the
two phenotypes. Whilst the current study is the first to investigate
KRAS mutations in codons 12, 13, 59 and 61 covering more than
97% of all reported mutations for KRAS in CRC, earlier studies
investigated only codon 12 of the KRAS gene [13,33]. Based on our
results this could explain the reported differences for KRAS in flat
adenomas observed in previous studies, since in the current study
a significant difference for codon 12 was observed while for the
whole KRAS gene this difference was absent. Other factors,
however, such as sample selection and different flat adenoma
subtypes could also influences the results observed in the previous
studies. KRAS mutations have previously been reported to be less
frequent in depressed (0-IIc) lesions [13,29] compared to other flat
subtypes and or polypoid lesions which is consistent with the
current study, where non of the four IIc adenomas showed a KRAS
mutation. Several studies suggested that KRAS mutations were
significantly more frequent in LST-G than in LST-F cases [32,34].
In the present study, the number of LST-G adenomas investigated
was too small to draw a general conclusion. There was, however,
a trend towards a higher mutation frequency in LST-G type
adenomas compared to the LST-F types (34.67% versus 26.73%).
In literature the NRAS mutation rate in CRC is around 3%
[35,36]. One study has investigated NRAS mutation frequency in
a very small series of flat adenomas showing a percentage of 25%
(2 out of 8 samples) [37]. The percentages in the present study are
around 1% in both flat and polypoid adenomas.
Mutation Analysis in Flat Adenomas
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41963
The current study confirms that BRAF and KRAS are mutually
exclusive [38] and that BRAF mutations are associated with the
serrated phenotype [39]. The BRAF mutation frequency of
polypoid and flat adenomas was similar to the reported literature
[16,29,32]. Whereas BRAF mutations are relatively more common
in MSI colorectal carcinomas, for adenomas this is less straightfor-
ward [40]. As we reported only one MSI adenoma (similar to
previous findings [14,41]) we did not find an association between
BRAF mutations and MSI.
Overall, when combining all the gene mutations of the RAS-
RAF-MAPK pathway, no significant differences were detected
between flat adenomas and polypoid colorectal adenomas.
PI3K-AKT Pathway
In the current study, no mutations were found in the PI3KCA
and PIK3R1 nor in the negative regulator of the PI3K-AKT
pathway, the PTEN gene. The mutation frequency in carcinomas
for PIK3CA varies between 10–30% [42,43] and mostly affects
exons 9 and 20 (both completely covered in our analysis). In
colorectal adenomas, however, PIK3CA mutations are less
common, with mutation frequencies around 3%, indicating that
mutations in PIK3CA generally would arise late in tumorigenesis
[42]. Furthermore, these mutations have been reported to be
uncommon (0 to 3%) in flat lesions and without significant
difference compared to polypoid adenomas [29,32]. Together
these results indicate that mutation-driven activation of the PI3K-
AKT pathway rarely occurs in polypoid adenomas as well as in flat
adenomas.
Cyclin Dependent Kinases
Cyclins, together with cyclin-dependent kinases, regulate the
cell cycle. Disruption of cyclin activity can lead to cell cycle arrest
or uncontrolled cell cycle progression. FBXW7 is a component of
a ubiquitin ligase complex (F-box complex) which targets among
others cyclin E and MYC, for degradation. Mutations in FBXW7
are often missense mutations, mostly found in the WD40 domain
[44]. Two of the mutations (R505C and R465C) described in the
current study are in this domain and one (R275*) is outside this
domain, in a non-sense mutation cluster (aa 220–393) [45].
Wnt-signaling
Mutations in CTNNB1 (b-catenin) have been reported as an
alternative to APC mutations [12] and were found more frequently
in small colorectal adenomas [46]. However, more recent studies
fail to confirm this [47]. In the current study two mutations were
reported, one in a small and one in a large adenoma. No
significant difference between polypoid and flat adenomas was
detected, which is in line with earlier findings [29].
In the present study, one of the largest investigating APC
mutations in flat adenomas, a significantly lower frequency of APC
truncating mutations was observed in flat adenomas compared to
polypoid adenomas (30.27% versus 48.49%, respectively) similar
to an earlier observations in a smaller sample set investigating
depressed adenomas [13]. In the present series none of the
mutations in subtype IIa were caused due to nucleotide deletions,
which therefore would indicate these deletions to be rare in this
type of lesions. However, Umetani et al, did find APC mutations
due to nucleotide deletions, which contradicts this observation
[13]. Between the different subtypes of flat lesions there was no
significant difference and all showed lower mutation frequencies
compared to polypoid adenomas.
In the current study two adenomas harbored a double mutation.
Double mutations are not unique and are frequently reported in
the literature especially in familial adenomatous polyposis (FAP)
patients [48,49].
Originally, all mutations in APC were considered to be equal in
their impact on tumorigenesis. However, the ‘‘just-right’’ signaling
model shows that there is a strong selective pressure on the level of
b-catenin signaling resulting from specific APC mutations (i.e.
depending on the mutation side, the truncated APC protein
contains different amounts of b-catenin degradation repeats) [48].
In addition, it has been shown that the position of mutations in the
APC gene differ along the GI tract [48] and that mutations at
different positions yield different phenotypes in FAP patients [50].
In the current study a difference between left and right colon was
observed, but no differences between flat and polypoid adenomas
were observed.
From this study it appears that APC mutations and thus possibly
the Wnt-signaling in general, would play a less prominent role in
flat adenomas than in polypoid adenomas. However, alternative
modes of Wnt activation, like mutations outside the MCR of APC
(not investigated in the present study), promoter CpG-island
methylation of APC or other Wnt related genes, or altered
expression of relevant microRNAs cannot be excluded [51,52].
Interestingly, we found that loss of chromosome 5q is significantly
more frequent in flat adenomas compared to polypoid adenomas,
which also may affect APC located within this loss. At the same
time we observed fewer APC mutations in flat adenomas,
compared to polypoid adenomas [11]. Thus the picture of
mechanisms of APC disruption in flat adenomas may be more
complex than in polypoid adenomas. As a consequence these
alternative APC disrupting mechanisms that occur in flat lesions
may also have different effects on molecular processes that are
involved in the pathogenesis of CRC, such as stability of the
cytoskeleton [53], or chromosomal instability [54–56], resulting in
a more aggressive behavior of flat lesions.
Despite the relatively large amount of flat adenomas in the
current study, the number of lesions from specific subtypes (i.e. IIc
and LST-G) was relatively low, which may be due to the fact that
overall these subtypes are less common. Therefore strong
conclusions about potential differences in mutation frequencies
in one of the subtypes cannot be drawn from this study.
All the mutations investigated in the current study have been
described as somatic mutations (in the COMSMIC database),
however the presence of germ line mutations cannot be excluded
due to the lack of matched normal DNA.
In conclusion, besides APC, no significant differences were
found for the investigated mutations between flat adenomas and
polypoid adenomas. In contrast to previous observations, the
RAS-RAF-MAPK pathway was equally affected by mutations in
both flat adenomas and polypoid adenomas. Although, flat
adenomas showed a lower frequency of APC mutations compared
to polypoid adenomas, they were previously found to have higher
frequency of chromosome 5q loss, including the APC gene locus.
Therefore the difference in phenotype between flat and polypoid
adenomas may be associated with alternative mechanisms of
disrupting the Wnt-pathway.
Supporting Information
Table S1 Frequency of A) BRAF, B) NRAS, C) KRAS, D)
PIK3CA, E) PIK3R1, F) EGFR, G) PTEN, H) MAP2K4, I)
SMAD4, J) FBXW7, K) CTNNB1, L) STK11, M) PDGFRA
and N) APC mutations according to the COSMIC
database for carcinomas and adenomas. -; no data
available. Relative mutation distribution = percentage of specific
mutation within the mutation subpopulation. Absolute mutation
Mutation Analysis in Flat Adenomas
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41963
frequency = percentage of specific mutations in the whole study
population = incidence. Grey blocks represent excluded assays.
(DOC)
Table S2 Frequency of A) BRAF, B) NRAS, C) KRAS, D)
PIK3CA, E) PIK3R1, F) EGFR, G) PTEN, H) MAP2K4, I)
SMAD4, J) FBXW7, K) CTNNB1, L) STK11, M) PDGFRA
and N) APC mutations in the flat and polypoid
adenomas. CI; 95% confidence interval, #; number of samples
where all assays succeeded, ##; mutation percentage based on the
random input algorithm, ###; p-value calculated based on
random impute algorithm.
(DOC)
Table S3 Overview of all mutated samples. MSS;
microsatelite stable, MSI; microsatelite instable, SSL; sessile
serrated lesion, TSA; traditional serrated adenoma, Italic; silent
mutation, #;Mutation not described before in colorectal adeno-
mas, -; no data available.
(DOC)
Author Contributions
Conceived and designed the experiments: DL MvE CM GM. Performed
the experiments: QV AS SM DL B. Claes. Analyzed the data: QV B.
Carvalho MvdW. Contributed reagents/materials/analysis tools: NvG
MK HG BR PQ CM. Wrote the paper: QV B. Carvalho B. Claes GM
HG.
References
1. Muto T, Kamiya J, Sawada T, Konishi F, Sugihara K, et al. (1985) Small "flat
adenoma" of the large bowel with special reference to its clinicopathologic
features. Dis Colon Rectum 28: 847–851.
2. Kudo S, Tamura S, Hirota S, Sano Y, Yamano H, et al. (1995) The problem of
de novo colorectal carcinoma. Eur J Cancer 31A: 1118–1120.
3. Togashi K, Konishi F, Koinuma K, Ishitsuka T, Kojima M, et al. (2003) Flat
and depressed lesions of the colon and rectum: Pathogenesis and clinical
management. Ann Acad Med Singapore 32: 152–158.
4. Bianco MA, Cipolletta L, Rotondano G, Buffoli F, Gizzi G, et al. (2010)
Prevalence of nonpolypoid colorectal neoplasia: an Italian multicenter
observational study. Endoscopy 42: 279–285.
5. Rembacken BJ, Fujii T, Cairns A, Dixon MF, Yoshida S, et al. (2000) Flat and
depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the
UK. Lancet 355: 1211–1214.
6. Soetikno RM, Kaltenbach T, Rouse RV, Park W, Maheshwari A, et al. (2008)
Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in
asymptomatic and symptomatic adults. JAMA 299: 1027–1035.
7. Wolber RA, Owen DA (1991) Flat adenomas of the colon. Hum Pathol 22: 70–
74.
8. Sillars-Hardebol AH, Carvalho B, van EM, Fijneman RJ, Meijer GA (2011) The
adenoma hunt in colorectal cancer screening: defining the target. J Pathol.
9. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell
144: 646–674.
10. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell
87: 159–170.
11. Voorham QJ, Carvalho B, Spiertz AJ, van Grieken NC, Mongera S, et al. (2012)
Chromosome 5q loss in colorectal flat adenomas. Clin Cancer Res. DOI:
10.1158/1078–0432.CCR-11–2385.
12. Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, et al. (1998)
Activation of the beta-catenin gene by interstitial deletions involving exon 3 in
primary colorectal carcinomas without adenomatous polyposis coli mutations.
Cancer Res 58: 1021–1026.
13. Umetani N, Sasaki S, Masaki T, Watanabe T, Matsuda K, et al. (2000)
Involvement of APC and K-ras mutation in non-polypoid colorectal tumori-
genesis. Br J Cancer 82: 9–15.
14. Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, et al. (2001) Genetic
pathways in the evolution of morphologically distinct colorectal neoplasms.
Cancer Res 61: 2676–2683.
15. Noro A, Sugai T, Habano W, Nakamura S (2003) Analysis of Ki-ras and p53
gene mutations in laterally spreading tumors of the colorectum. Pathol Int 53:
828–836.
16. Takahashi T, Nosho K, Yamamoto H, Mikami M, Taniguchi H, et al. (2007)
Flat-type colorectal advanced adenomas (laterally spreading tumors) have
different genetic and epigenetic alterations from protruded-type advanced
adenomas. Mod Pathol 20: 139–147.
17. Yoshida S, Ikehara N, Aoyama N, Shirasaka D, Sakashita M, et al. (2008)
Relationship of BRAF mutation, morphology, and apoptosis in early colorectal
cancer. Int J Colorectal Dis 23: 7–13.
18. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus
coding sequences of human breast and colorectal cancers. Science 314: 268–274.
19. Jaramillo E, Watanabe M, Slezak P, Rubio C (1995) Flat neoplastic lesions of the
colon and rectum detected by high-resolution video endoscopy and chromo-
scopy. Gastrointest Endosc 42: 114–122.
20. Urban O, Vitek P, Fojtik P, Kliment M, Janik D, et al. (2008) Laterally
spreading tumors–experience based on 138 consecutive cases. Hepatogastroen-
terology 55: 351–355.
21. Endoscopic Classification Review Group (2003) The Paris endoscopic
classification of superficial neoplastic lesions: esophagus, stomach, and colon:
November 30 to December 1, 2002. Gastrointest Endosc 58: S3–43.
22. Kudo S (1993) Endoscopic mucosal resection of flat and depressed types of early
colorectal cancer. Endoscopy 25: 455–461.
23. Weiss MM, Hermsen MA, Meijer GA, van Grieken NC, Baak JP, et al. (1999)
Comparative genomic hybridisation. Mol Pathol 52: 243–251.
24. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, et al. (2004) The
COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
(update 26 July 2010). Br J Cancer 91: 355–358.
25. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of
cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal
cancer: a retrospective consortium analysis. Lancet Oncol 11: 753–762.
26. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, et al. (2007)
High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:
347–351.
27. Diosdado B, Buffart TE, Watkins R, Carvalho B, Ylstra B, et al. (2010) High-
resolution array comparative genomic hybridization in sporadic and celiac
disease-related small bowel adenocarcinomas. Clin Cancer Res 16: 1391–1401.
28. Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, et al. (2002) Colorectal
adenoma to carcinoma progression follows multiple pathways of chromosomal
instability. Gastroenterology 123: 1109–1119.
29. Mikami M, Nosho K, Yamamoto H, Takahashi T, Maehata T, et al. (2006)
Mutational analysis of beta-catenin and the RAS-RAF signalling pathway in
early flat-type colorectal tumours. Eur J Cancer 42: 3065–3072.
30. Sakamoto N, Terai T, Ajioka Y, Abe S, Kobayasi O, et al. (2004) Frequent
hypermethylation of RASSF1A in early flat-type colorectal tumors. Oncogene
23: 8900–8907.
31. Minamoto T, Sawaguchi K, Mai M, Yamashita N, Sugimura T, et al. (1994)
Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and
adenocarcinomas. Cancer Res 54: 2841–2844.
32. Sugimoto T, Ohta M, Ikenoue T, Yamada A, Tada M, et al. (2010)
Macroscopic morphologic subtypes of laterally spreading colorectal tumors
showing distinct molecular alterations. Int J Cancer 127: 1562–1569.
33. Yamagata S, Muto T, Uchida Y, Masaki T, Higuchi Y, et al. (1995) Polypoid
growth and K-ras codon 12 mutation in colorectal cancer. Cancer 75: 953–957.
34. Hiraoka S, Kato J, Tatsukawa M, Harada K, Fujita H, et al. (2006) Laterally
spreading type of colorectal adenoma exhibits a unique methylation phenotype
and K-ras mutations. Gastroenterology 131: 379–389.
35. Oudejans JJ, Slebos RJ, Zoetmulder FA, Mooi WJ, Rodenhuis S (1991)
Differential activation of ras genes by point mutation in human colon cancer
with metastases to either lung or liver. Int J Cancer 49: 875–879.
36. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. (1988)
Genetic alterations during colorectal-tumor development. N Engl J Med 319:
525–532.
37. Fujimori T, Satonaka K, Yamamura-Idei Y, Nagasako K, Maeda S (1994) Non-
involvement of ras mutations in flat colorectal adenomas and carcinomas.
Int J Cancer 57: 51–55.
38. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, et al. (2002) Similarity of the
phenotypic patterns associated with BRAF and KRAS mutations in colorectal
neoplasia. Cancer Res 62: 6451–6455.
39. Leggett B, Whitehall V (2010) Role of the serrated pathway in colorectal cancer
pathogenesis. Gastroenterology 138: 2088–2100.
40. Chan TL, Zhao W, Leung SY, Yuen ST (2003) BRAF and KRAS mutations in
colorectal hyperplastic polyps and serrated adenomas. Cancer Res 63: 4878–
4881.
41. Young J, Leggett B, Gustafson C, Ward M, Searle J, et al. (1993) Genomic
instability occurs in colorectal carcinomas but not in adenomas. Hum Mutat 2:
351–354.
42. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency
of mutations of the PIK3CA gene in human cancers. Science 304: 554.
43. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, et al. (2005) The
prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41:
1649–1654.
44. Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, et al. (2004)
Inactivation of hCDC4 can cause chromosomal instability. Nature 428: 77–81.
45. Gylfe AE, Sirkia J, Ahlsten M, Jarvinen H, Mecklin JP, et al. (2010) Somatic
mutations and germline sequence variants in patients with familial colorectal
cancer. Int J Cancer 127: 2974–2980.
Mutation Analysis in Flat Adenomas
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e41963
46. Samowitz WS, Powers MD, Spirio LN, Nollet F, van RF, et al. (1999) Beta-
catenin mutations are more frequent in small colorectal adenomas than in larger
adenomas and invasive carcinomas. Cancer Res 59: 1442–1444.
47. Johnson V, Volikos E, Halford SE, Eftekhar Sadat ET, Popat S, et al. (2005)
Exon 3 beta-catenin mutations are specifically associated with colorectal
carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut 54:
264–267.
48. Albuquerque C, Baltazar C, Filipe B, Penha F, Pereira T, et al. (2010) Colorectal
cancers show distinct mutation spectra in members of the canonical WNT
signaling pathway according to their anatomical location and type of genetic
instability. Genes Chromosomes Cancer 49: 746–759.
49. van Wyk R, Slezak P, Kotze MJ, Jaramillo E, Koizumi K, et al. (1999) Multiple
APC mutations in sporadic flat colorectal adenomas. Eur J Hum Genet 7: 928–
932.
50. Fearnhead NS, Britton MP, Bodmer WF (2001) The ABC of APC. Hum Mol
Genet 10: 721–733.
51. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, et al. (2000)
Analysis of adenomatous polyposis coli promoter hypermethylation in human
cancer. Cancer Res 60: 4366–4371.
52. Huang K, Zhang JX, Han L, You YP, Jiang T, et al. (2010) MicroRNA roles in
beta-catenin pathway. Mol Cancer 9: 252.
53. Akiyama T, Kawasaki Y (2006) Wnt signalling and the actin cytoskeleton.
Oncogene 25: 7538–7544.
54. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, et al. (2001) Mutations
in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol
3: 433–438.
55. Tighe A, Johnson VL, Taylor SS (2004) Truncating APC mutations have
dominant effects on proliferation, spindle checkpoint control, survival and
chromosome stability. J Cell Sci 117: 6339–6353.
56. Alberici P, Fodde R (2006) The role of the APC tumor suppressor in
chromosomal instability. Genome Dyn 1: 149–170.
Mutation Analysis in Flat Adenomas
PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e41963
